Abstract
To explore apolipoprotein E gene variants distribution among the patients of Alzheimer’s disease and vascular dementia for the elderly community population in Nanking, the polymerase chain reaction and restriction fragment length polymorphism techniques were employed to analyze the gene frequency of apolipoprotein E (ApoE) for 113 cases with Alzheimer’s disease (AD), 85 cases with vascular dementia (VaD), 147 cases with questionable dementia (QD), and 396 dementia-free controls. It was found that ApoE ε4 gene container (37.17%) and allele frequency (21.24±2.72) of ApoE ε4 in AD group were significantly higher than those in both control and VaD group (p<0.05). With the increment of ε4 gene dose, the incidence of the AD was significantly increased. Compared with the control group, ApoE ε4 had risk ratio (RR) of 1.82 to develop AD (p =4e-4), and attributable risk percentage (ARP) of 45%. These results suggest that ApoE ε4 gene may be responsible for up to 45% of the genetic component of Alzheimer’s disease, and may act as a discriminator between AD and VaD as well.
Keywords: Alzheimer’s disease, vascular dementia, apolipoprotein E.
Graphical Abstract
Medicinal Chemistry
Title:Apolipoprotein E Gene Variants of Alzheimer's Disease and Vascular Dementia Patients in a Community Population of Nanking
Volume: 10 Issue: 8
Author(s): Wen-Zheng Chu, Li Gong, Ying-Qiu Xu, Guo-Hua Cai and Kuo-Chen Chou
Affiliation:
Keywords: Alzheimer’s disease, vascular dementia, apolipoprotein E.
Abstract: To explore apolipoprotein E gene variants distribution among the patients of Alzheimer’s disease and vascular dementia for the elderly community population in Nanking, the polymerase chain reaction and restriction fragment length polymorphism techniques were employed to analyze the gene frequency of apolipoprotein E (ApoE) for 113 cases with Alzheimer’s disease (AD), 85 cases with vascular dementia (VaD), 147 cases with questionable dementia (QD), and 396 dementia-free controls. It was found that ApoE ε4 gene container (37.17%) and allele frequency (21.24±2.72) of ApoE ε4 in AD group were significantly higher than those in both control and VaD group (p<0.05). With the increment of ε4 gene dose, the incidence of the AD was significantly increased. Compared with the control group, ApoE ε4 had risk ratio (RR) of 1.82 to develop AD (p =4e-4), and attributable risk percentage (ARP) of 45%. These results suggest that ApoE ε4 gene may be responsible for up to 45% of the genetic component of Alzheimer’s disease, and may act as a discriminator between AD and VaD as well.
Export Options
About this article
Cite this article as:
Chu Wen-Zheng, Gong Li, Xu Ying-Qiu, Cai Guo-Hua and Chou Kuo-Chen, Apolipoprotein E Gene Variants of Alzheimer's Disease and Vascular Dementia Patients in a Community Population of Nanking, Medicinal Chemistry 2014; 10 (8) . https://dx.doi.org/10.2174/1573406410666140327120714
DOI https://dx.doi.org/10.2174/1573406410666140327120714 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Potential of Vasoactive Intestinal Peptide and its Receptors in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Cognitive Impairment and Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Preventive Effect of Soybean on Brain Aging and Amyloid-β Accumulation: Comprehensive Analysis of Brain Gene Expression
Recent Patents on Food, Nutrition & Agriculture Opiate Addiction Therapies and HIV-1 Tat: Interactive Effects on Glial [Ca<sup>2+</sup>]<sub>i</sub>, Oxyradical and Neuroinflammatory Chemokine Production and Correlative Neurotoxicity
Current HIV Research Disease Progression in HIV Late Presenters: the Role of HIV Clinical Indicator Diseases Prior to HIV Diagnosis
Current HIV Research Role of Opioid Antagonists in the Treatment of Women with Glucoregulation Abnormalities
Current Pharmaceutical Design Brain Perfusion In Sepsis
Current Vascular Pharmacology Proteoglycans and Glycosaminoglycans in Misfolded Proteins Formation in Alzheimer's Disease
Protein & Peptide Letters Oxidative Stress, Mitochondrial Abnormalities and Proteins Deposition: Multitarget Approaches in Alzheimer's Disease
Current Topics in Medicinal Chemistry Synthetic Curcumin Analogs as Inhibitors of β -Amyloid Peptide Aggregation: Potential Therapeutic and Diagnostic Agents for Alzheimer's Disease
Mini-Reviews in Medicinal Chemistry Are Major Depressive Disorder and Diabetes Mellitus Amyloidogenic Conditions?
CNS & Neurological Disorders - Drug Targets Promising Therapies for Alzheimer's Disease
Current Pharmaceutical Design The Anti-Inflammatory Role of Minocycline in Alzheimer´s Disease
Current Alzheimer Research Infectious Burden: A New Risk Factor and Treatment Target for Atherosclerosis
Infectious Disorders - Drug Targets MiR-335-5p Inhibits β-Amyloid (Aβ) Accumulation to Attenuate Cognitive Deficits Through Targeting c-jun-N-terminal Kinase 3 in Alzheimer’s Disease
Current Neurovascular Research (Pro)renin Receptor as a New Drug Target
Current Pharmaceutical Design Role of Mammalian Target of Rapamycin in Atherosclerosis
Current Molecular Medicine Cholinesterases: Roles in the Brain During Health and Disease
Current Alzheimer Research Potential for Stem Cells Therapy in Alzheimer’s Disease: Do Neurotrophic Factors Play Critical Role?
Current Alzheimer Research Placebos Used in Clinical Trials for Chinese Herbal Medicine
Recent Patents on Inflammation & Allergy Drug Discovery